The IMMU-132-01 trial (NCT01631552) we mentioned earlier has confirmed SG in NSCLC (n = 47), SCLC (small cell lung cancer, n = 50), HR+/HER2 − metastatic breast cancer (n = 54), mTNBC (n = 108) and mUC (metastatic urothelial cancer, n = 45) with anti-tumor activity [70]. Here, ERBB2 is linked to small cell lung carcinoma.